Xylitol Use for Decolonization of C. Difficile in Patients With IBD

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2032

Study Completion Date

January 1, 2033

Conditions
Inflammatory Bowel DiseasesClostridioides Difficile Infection
Interventions
DRUG

Xylitol

Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.

DRUG

Placebo

The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER